Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,175.97 -23.72 -0.74%
FTSE 100 6,674.74 -7.02 -0.11%
DAX 9,544.19 -55.90 -0.58%
Ticker Volume Price Price Delta
NIKKEI 14,527.36 -18.91 -0.13%
TOPIX 1,171.09 -2.72 -0.23%
HANG SENG 22,530.35 20.71 0.09%

SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior



   SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex
  Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the
  board of directors violated fiduciary duties owed to Vertex shareholders.

PR Newswire

NEW YORK, Nov. 27, 2012

NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Morgan & Morgan announces an
investigation into whether certain officers and directors of Vertex breached
their fiduciary duties to VRTX shareholders in connection with Vertex's recent
public acknowledgement that it made inaccurate disclosures about the Phase 2
clinical studies of VX-909 and Kalydeco, two experimental drugs in clinical
trials.  No decision to file a lawsuit has been made.  If you are a current
shareholder of Vertex Pharmaceuticals and are interested in learning more
about our Vertex (VRTX) shareholder lawsuit investigation, please contact
George Pressly, Esq. at 1 (800) 631-6234 or email George at
info@morgansecuritieslaw.com.

On May 7, 2012, Vertex issued a press release claiming that patients who
received VX-909 and Kalydeco during a phase 2 clinical trial showed
significant improvement in their lung functions. Published reports state that
between May 7, 2012 and May 25, 2012, certain Vertex officers and directors
sold over $22 million of their personally owned shares. On May 29, 2012,
Vertex acknowledged publicly that the results from its clinical trials were
not as positive as previously indicated. On June 27, 2012 Vertex admitted that
the May 7th statements were simply inaccurate.   Vertex's stock price declined
significantly on the news.

About Morgan & Morgan
Morgan & Morgan is one of the nation's largest 200 law firms. In addition to
securities law, the firm also practices in the areas of antitrust, personal
injury, consumer protection, overtime, and product liability.  All of the
Firm's legal endeavors are rooted in its core mission: provide investor and
consumer protection and always fight "for the people." 

Attorney advertising. Prior results do not guarantee a similar outcome.

Contact:
Morgan & Morgan
Peter Safirstein, Esq.
Five Penn Plaza
23rd Floor
New York, NY  10001
1-800-631-6234
info@morgansecuritieslaw.com

 

SOURCE Morgan & Morgan

Website: http://www.securitieslawfirm.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement